Overhauling CAR T Cells to Improve Efficacy, Safety and Cost

Autor(es)

Chicaybam, Leonardo ^{[1, 2]} ; Bonamino, Martin H. ^{[1, 2]} ; Luckow Invitti, Adriana ^[3] ; Bortman Rozenchan, Patricia ^[4] ; de Luna Vieira, Igor ^[5] ; Strauss, Bryan E. ^[5]

Afiliação do(s) autor(es)

^[1] Fundacao Inst Oswaldo Cruz FIOCRUZ, Pesquisa & Colecoes Biol, BR-21040900 Rio De Janeiro - Brazil

^[2] Inst Nacl Canc INCA, Programa Imunol & Biol Tumores Coordenacao Pesqui, BR-20231050 Rio De Janeiro - Brazil

^[3] Fed Univ Sao Paulo UNIFESP, EPM, Colsan Beneficial Blood Collect Assoc, Dept Gynecol, BR-04039032 Sao Paulo - Brazil

^[4] Celluris, BR-05508000 Sao Paulo - Brazil

^[5] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, Ctr Invest Translac Oncol, BR-01246000 Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CANCERS; v. 12, n. 9 SEP 2020.
• Citações Web of Science: 0

Resumo

Gene therapy is now surpassing 30 years of clinical experience and in that time a variety of approaches has been applied for the treatment of a wide range of pathologies. While the promise of gene therapy was over-stated in the 1990's, the following decades were met with polar extremes between demonstrable success and devastating setbacks. Currently, the field of gene therapy is enjoying the rewards of overcoming the hurdles that come with turning new ideas into safe and reliable treatments, including for cancer. Among these modalities, the modification of T cells with chimeric antigen receptors (CAR-T cells) has met with clear success and holds great promise for the future treatment of cancer. We detail a series of considerations for the improvement of the CAR-T cell approach, including the design of the CAR, routes of gene transfer, introduction of CARs in natural killer and other cell types, combining the CAR approach with checkpoint blockade or oncolytic viruses, improving pre-clinical models as well as means for reducing cost and, thus, making this technology more widely available. While CAR-T cells serve as a prime example of translating novel ideas into effective treatments, certainly the lessons learned will serve to accelerate the current and future development of gene therapy drugs. (AU)

• Processo FAPESP: 15/26580-9 - Terapia gênica do câncer: alinhamento estratégico para estudos translacionais
• Beneficiário: Bryan Eric Strauss
• Modalidade de apoio: Auxílio à Pesquisa - Temático